<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460629</url>
  </required_header>
  <id_info>
    <org_study_id>EK126092000</org_study_id>
    <nct_id>NCT00460629</nct_id>
  </id_info>
  <brief_title>Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation</brief_title>
  <official_title>Specific Cellular Immunotherapy in Patients With Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efforts to decrease the risk of GvHD by depleting T cells from the graft in CML patients have
      been complicated by an increased incidence of leukemia-relapse. Newer protocols using CD34+
      selected hematopoietic cells from matched-sibling donors and subsequent infusion of T cells
      in incremental doses to treat or avoid relapse of disease seem to be more promising. In this
      study, we try to further optimize this approach by the prophylactic infusion of cytotoxic T
      cells activated ex-vivo against leukemia-associated/specific antigens using peptide-pulsed
      dendritic cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The conditioning protocol contains:

      Total Body Irradiation 8-12 Gy (4-6 x 2 Gy, a 2 x/die) day -9 to-7 Thiotepa 10 mg/kg (2 x 5
      mg/kg) day -5 Fludarabine 200 mg/m2 (5 x 40 mg/m2) day -6 to-2 ATG Fresenius 25 mg/kg (5 x 5
      mg/kg) day -6 to-2 Cyclosporine A 1 mg/kg Day -10 to-3

      on day 0 CD34+ cells after immunomagnetic selection are infused. &gt; 4 x 10e6/kg CD34 cells/kg
      are required.

      On days 28, 56 and 112 after transplantation, cytotoxic T cells generated in-vitro are
      infused in patients who do not have signs of acute GvHD.

      Regular follow-up compromises immune monitoring including Tetramer analyses of
      Peptide-reactive T cells
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of the infusion of in-vitro activated donor T cells</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>kinetic of BCR-ABL load after transplantation</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute and chronic GvHD</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infectious complications</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Application of activated donor T cells</intervention_name>
    <description>Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60

          -  Ph+ CML

          -  HLA A0201, 0301, 1101, B0801

          -  BCR-ABL b3a2 positive

          -  no significant comorbidities

          -  resistance or intolerance of imatinib

        Exclusion Criteria:

          -  HIV positive

          -  blast crisis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bornh√§user, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Clinic, University Hospital Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Bornhauser M, Thiede C, Babatz J, Schetelig J, Illmer T, Kiani A, Platzbecker U, Herr W, Rieber EP, Ehninger G, Schmitz M. Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell transplantation. Leukemia. 2006 Nov;20(11):2055-7. Epub 2006 Aug 31.</citation>
    <PMID>16990776</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2007</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adoptive immunotherapy</keyword>
  <keyword>BCR-ABL reactive T cells</keyword>
  <keyword>Allogeneic Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

